Maintenance Chemotherapy for Patients with Rhabdomyosarcoma.
low-dose chemotherapy
maintenance chemotherapy
metronomic chemotherapy
rhabdomyosarcoma
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
07 Aug 2023
07 Aug 2023
Historique:
received:
22
06
2023
revised:
28
07
2023
accepted:
28
07
2023
medline:
12
8
2023
pubmed:
12
8
2023
entrez:
12
8
2023
Statut:
epublish
Résumé
Maintenance chemotherapy (MC) defines the administration of prolonged relatively low-intensity chemotherapy with the aim of "maintaining" tumor complete remission. This paper aims to report an update of the RMS2005 trial, which demonstrated better survival for patients with high-risk localized rhabdomyosarcoma (RMS) when MC with vinorelbine and low-dose cyclophosphamide was added to standard chemotherapy, and to discuss the published experience on MC in RMS. In the RMS2005 study, the outcome for patients receiving MC vs. those who stopped the treatment remains superior, with a 5-year disease-free survival of 78.1% vs. 70.1% (
Identifiants
pubmed: 37568826
pii: cancers15154012
doi: 10.3390/cancers15154012
pmc: PMC10417571
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Eur J Cancer. 2017 Sep;83:177-184
pubmed: 28738258
Cancer. 2018 Aug 1;124(15):3201-3209
pubmed: 29797665
Pediatr Blood Cancer. 2009 Jul;52(7):772-6
pubmed: 19165889
Lancet Oncol. 2019 Nov;20(11):1566-1575
pubmed: 31562043
J Clin Invest. 2000 Apr;105(8):R15-24
pubmed: 10772661
Lancet Oncol. 2018 Aug;19(8):1061-1071
pubmed: 29941280
JCO Precis Oncol. 2022 Oct;6:e2100534
pubmed: 36265118
Biomolecules. 2022 Feb 24;12(3):
pubmed: 35327550
Lancet Oncol. 2005 Sep;6(9):649-58
pubmed: 16129365
J Clin Oncol. 2013 Jul 1;31(19):2485-92
pubmed: 23715582
Cancer Res. 2000 Apr 1;60(7):1878-86
pubmed: 10766175
Trends Cancer. 2020 Oct;6(10):819-828
pubmed: 32601045
Crit Rev Oncol Hematol. 2012 Apr;82(1):40-50
pubmed: 21641231
Cancer Med. 2023 May;12(9):10222-10229
pubmed: 37016270
Pediatr Blood Cancer. 2020 Sep;67(9):e28508
pubmed: 32658380
J Clin Oncol. 2012 Jan 1;30(1):78-84
pubmed: 22067397
Pediatr Blood Cancer. 2011 May;56(5):725-32
pubmed: 21370403
Pediatr Blood Cancer. 2021 Mar;68(3):e28832
pubmed: 33245207
J Clin Oncol. 2022 Nov 10;40(32):3730-3740
pubmed: 35709412
Mol Oncol. 2022 May;16(10):2071-2085
pubmed: 35212153
Cancers (Basel). 2023 Mar 30;15(7):
pubmed: 37046711
Cancer Treat Rev. 2018 Jul;68:94-101
pubmed: 29940525
Eur J Cancer. 2012 Oct;48(15):2409-16
pubmed: 22633624
Cancers (Basel). 2022 Feb 11;14(4):
pubmed: 35205646
J Clin Oncol. 2005 Oct 1;23(28):7135-42
pubmed: 16192597
Cancer. 2017 May 15;123(6):1003-1010
pubmed: 28263383
Gulf J Oncolog. 2019 May;1(30):22-28
pubmed: 31242978
Pediatr Blood Cancer. 2008 Apr;50(4):739-45
pubmed: 18286501
Oncogene. 2005 Dec 1;24(54):8025-37
pubmed: 16116481
Cancer. 2002 Jun 15;94(12):3263-8
pubmed: 12115359
Front Pharmacol. 2023 May 03;14:1132219
pubmed: 37205905
Int J Mol Sci. 2020 Jan 31;21(3):
pubmed: 32023984
Pediatr Blood Cancer. 2020 May;67(5):e28174
pubmed: 31994316
Cancer. 2004 Oct 1;101(7):1664-71
pubmed: 15378498
Cancer Chemother Pharmacol. 2022 Jul;90(1):29-44
pubmed: 35751658
Trends Cancer. 2019 Dec;5(12):756-759
pubmed: 31813450
Acta Oncol. 2020 Sep;59(9):1084-1090
pubmed: 32400254
Leukemia. 2022 Jul;36(7):1749-1758
pubmed: 35654820
Cancer. 1993 Mar 1;71(5):1904-22
pubmed: 8448756